106 related articles for article (PubMed ID: 21187353)
1. Virological response with fully active etravirine: pooled results from the DUET-1 and DUET-2 trials.
Clumeck N; Cahn P; Molina JM; Mills A; Nijs S; Vingerhoets J; Witek J
Int J STD AIDS; 2010 Nov; 21(11):738-40. PubMed ID: 21187353
[TBL] [Abstract][Full Text] [Related]
2. Impact of the background regimen on virologic response to etravirine: pooled 48-week analysis of DUET-1 and -2.
Trottier B; Di Perri G; Madruga JV; Peeters M; Vingerhoets J; Picchio G; Woodfall BJ
HIV Clin Trials; 2010; 11(4):175-85. PubMed ID: 20974573
[TBL] [Abstract][Full Text] [Related]
3. Efficacy and safety of etravirine at week 96 in treatment-experienced HIV type-1-infected patients in the DUET-1 and DUET-2 trials.
Katlama C; Clotet B; Mills A; Trottier B; Molina JM; Grinsztejn B; Towner W; Haubrich R; Nijs S; Vingerhoets J; Woodfall B; Witek J
Antivir Ther; 2010; 15(7):1045-52. PubMed ID: 21041921
[TBL] [Abstract][Full Text] [Related]
4. Characterization of genotypic and phenotypic changes in HIV-1-infected patients with virologic failure on an etravirine-containing regimen in the DUET-1 and DUET-2 clinical studies.
Tambuyzer L; Vingerhoets J; Azijn H; Daems B; Nijs S; de Béthune MP; Picchio G
AIDS Res Hum Retroviruses; 2010 Nov; 26(11):1197-205. PubMed ID: 20854144
[TBL] [Abstract][Full Text] [Related]
5. Short communication: high effectiveness of etravirine in routine clinical practice in treatment-experienced HIV type 1-infected patients.
Santos JR; Llibre JM; Domingo P; Imaz A; Ferrer E; Podzamczer D; Bravo I; Ribera E; Videla S; Clotet B
AIDS Res Hum Retroviruses; 2011 Jul; 27(7):713-7. PubMed ID: 21114458
[TBL] [Abstract][Full Text] [Related]
6. Resistance profile of etravirine: combined analysis of baseline genotypic and phenotypic data from the randomized, controlled Phase III clinical studies.
Vingerhoets J; Tambuyzer L; Azijn H; Hoogstoel A; Nijs S; Peeters M; de Béthune MP; De Smedt G; Woodfall B; Picchio G
AIDS; 2010 Feb; 24(4):503-14. PubMed ID: 20051805
[TBL] [Abstract][Full Text] [Related]
7. Etravirine in combination with darunavir/ritonavir and optimized background regimen results in suppression of HIV replication in treatment-experienced patients. Evaluation of Katlama C, Haubrich R, Lalezari J, et al. Efficacy and safety of etravirine in treatment-experienced HIV-1 patients: pooled 48-week analysis of two randomized, controlled trials. AIDS 2009; 23: 2289-300.
Hull MW; Montaner JS
Expert Opin Pharmacother; 2010 Jun; 11(8):1433-7. PubMed ID: 20367279
[TBL] [Abstract][Full Text] [Related]
8. Similar predictions of etravirine sensitivity regardless of genotypic testing method used: comparison of available scoring systems.
Vingerhoets J; Nijs S; Tambuyzer L; Hoogstoel A; Anderson D; Picchio G
Antivir Ther; 2012; 17(8):1571-9. PubMed ID: 22869341
[TBL] [Abstract][Full Text] [Related]
9. Safety of etravirine in HIV-1/hepatitis B and/or C virus co-infected patients: pooled 96 week results from the Phase III DUET trials.
Clotet B; Clumeck N; Katlama C; Nijs S; Witek J
J Antimicrob Chemother; 2010 Nov; 65(11):2450-4. PubMed ID: 20801782
[TBL] [Abstract][Full Text] [Related]
10. Etravirine: a second-generation nonnucleoside reverse transcriptase inhibitor (NNRTI) active against NNRTI-resistant strains of HIV.
Schiller DS; Youssef-Bessler M
Clin Ther; 2009 Apr; 31(4):692-704. PubMed ID: 19446143
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of etravirine in treatment-experienced, HIV-1 patients: pooled 48 week analysis of two randomized, controlled trials.
Katlama C; Haubrich R; Lalezari J; Lazzarin A; Madruga JV; Molina JM; Schechter M; Peeters M; Picchio G; Vingerhoets J; Woodfall B; De Smedt G;
AIDS; 2009 Nov; 23(17):2289-300. PubMed ID: 19710593
[TBL] [Abstract][Full Text] [Related]
12. Short communication: activity of etravirine on different HIV type 1 subtypes: in vitro susceptibility in treatment-naive patients and week 48 pooled DUET study data.
Vingerhoets J; Azijn H; Tambuyzer L; Dierynck I; De Meyer S; Rimsky L; Nijs S; De Smedt G; de Béthune MP; Picchio G
AIDS Res Hum Retroviruses; 2010 Jun; 26(6):621-4. PubMed ID: 20507207
[TBL] [Abstract][Full Text] [Related]
13. Effects of etravirine versus placebo on health-related quality of life in treatment-experienced HIV patients as measured by the functional assessment of human immunodeficiency virus infection (FAHI) questionnaire in the DUET trials.
Cella D; Gilet H; Viala-Danten M; Peeters K; Dubois D; Martin S
HIV Clin Trials; 2010; 11(1):18-27. PubMed ID: 20400408
[TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of etravirine (TMC125) in treatment-experienced HIV-1-infected patients: 48-week results of a phase IIb trial.
Cohen CJ; Berger DS; Blick G; Grossman HA; Jayaweera DT; Shalit P; Thompson M; Peeters M; de Béthune MP; Voorspoels E; Mack R; Woodfall B
AIDS; 2009 Jan; 23(3):423-6. PubMed ID: 19114852
[TBL] [Abstract][Full Text] [Related]
15. The costs of full suppression of plasma HIV RNA in highly antiretroviral-experienced patients.
Hill AM; Cho M; Mrus JM
AIDS Rev; 2011; 13(1):41-8. PubMed ID: 21412388
[TBL] [Abstract][Full Text] [Related]
16. Switching to darunavir/ritonavir 800/100 mg once-daily containing regimen maintains virological control in fully suppressed pre-treated patients infected with HIV-1.
Ghosn J; Slama L; Chermak A; Houssaini A; Lambert-Niclot S; Schneider L; Fourn E; Duvivier C; Simon A; Courbon E; Murphy R; Flandre P; Peytavin G; Katlama C;
J Med Virol; 2013 Jan; 85(1):8-15. PubMed ID: 23024008
[TBL] [Abstract][Full Text] [Related]
17. Pooled week 96 results of the phase III DUET-1 and DUET-2 trials of etravirine: further analysis of adverse events and laboratory abnormalities of special interest.
Girard PM; Campbell TB; Grinsztejn B; Hartikainen J; Rachline A; Nijs S; Witek J
HIV Med; 2012 Aug; 13(7):427-35. PubMed ID: 22413938
[TBL] [Abstract][Full Text] [Related]
18. Resistance analyses in highly experienced patients failing raltegravir, etravirine and darunavir/ritonavir regimen.
Charpentier C; Roquebert B; Colin C; Taburet AM; Fagard C; Katlama C; Molina JM; Jacomet C; Brun-Vézinet F; Chêne G; Yazdanpanah Y; Descamps D;
AIDS; 2010 Nov; 24(17):2651-6. PubMed ID: 20802293
[TBL] [Abstract][Full Text] [Related]
19. Etravirine.
Deeks ED; Keating GM
Drugs; 2008; 68(16):2357-72. PubMed ID: 18973398
[TBL] [Abstract][Full Text] [Related]
20. Pharmacokinetics and antiretroviral response to darunavir/ritonavir and etravirine combination in patients with high-level viral resistance.
Boffito M; Winston A; Jackson A; Fletcher C; Pozniak A; Nelson M; Moyle G; Tolowinska I; Hoetelmans R; Miralles D; Gazzard B
AIDS; 2007 Jul; 21(11):1449-55. PubMed ID: 17589191
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
